Stem-cell transplantation in non-Hodgkin's lymphoma: Improving outcome

Anti-Cancer Drugs

Volumn 13, Issue SUPPL. 2, 2002, Pages

  Gianni, Alessandro M ^a   Berinstein, Neil L ^d   Evans, Paul A S ^b   López Guillermo, Armando ^c   Solano, Carlos ^d  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b LEEDS GENERAL INFIRMARY   (United Kingdom)

^c HOSPITAL CLÍNIC   (Spain)

^d NONE

Author keywords

Autologous stem cell transplantation; Graft versus host disease; Minimal residual disease; Polymerase chain reaction; Purging; Rituximab

Indexed keywords

GENE PRODUCT; PROTEIN BCL 1; PROTEIN BCL 2; RITUXIMAB; UNCLASSIFIED DRUG;

CANCER RECURRENCE; CONFERENCE PAPER; DISEASE MARKER; FOLLICULAR LYMPHOMA; GENE OVEREXPRESSION; GENE REARRANGEMENT; GRAFT VERSUS HOST REACTION; HUMAN; LYMPHOMA CELL; MANTLE CELL LYMPHOMA; MINIMAL RESIDUAL DISEASE; NONHODGKIN LYMPHOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EID: 0036879352     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200211002-00006     Document Type: Conference Paper

References (28)

1. Shipp MA, Abeloff MD, Antman KH, et al. International Consensus Conference on high-dose therapy with hematopoietic stem-cell transplantation in aggressive non-Hodgkin's lymphomas: report of the jury. Ann Oncol 1999; 10: 13-9.
2. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540-5.
3. Decaudin D, Brousse N, Brice P, et al. Efficacy of autologous stem cell transplantation in mantle cell lymphoma: a 3-year follow-up study. Bone Marrow Transplant 2000; 25: 251-6.
4. Bierman PJ, Vose JM, Anderson JR, Bishop MR, Kessinger A, Armitage JO. High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma. J Clin Oncol 1997; 15: 445-50.
5. Freedman AS, Neuberg D, Mauch P, et al. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood 1999; 94: 3325-33.
6. Liu Y, Hernandez AM, Shibata D, Cortopassi GA. BCL2 translocation frequency rises with age in humans. Proc Natl Acad Sci USA 1994; 91: 8910-14.
7. Gribben JG, Neuberg D, Freedman AS, et al. Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. Blood 1993; 81: 3449-57.
8. Lopez-Guillermo A, Cabanillas F, McLaughlin P, et al. Molecular response assessed by PCR is the most important factor predicting failure-free survival in indolent follicular lymphoma: update of the MDACC series. Ann Oncol 2000; 11(suppl 1): 137-40.
9. Colombat P, Salles G, Brousse N, et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 2001; 97: 101-6.
10. Campo E, Raffeld M, Jaffe ES. Mantle-cell lymphoma. Semin Hematol 1999; 36: 115-27.
11. Siebert R, Matthiesen P, Harder S, et al. Application of interphase cytogenetics for the detection of t(11;14)(q13;q32) in mantle cell lymphomas. Ann Oncol 1998; 9: 519-26.
12. Andersen NS, Donovan JW, Borus JS, et al. Failure of immunologic purging in mantle cell lymphoma assessed by polymerase chain reaction detection of minimal residual disease. Blood 1997; 90: 4212-21.
13. van Dongen JJ, Macintyre EA, Gabert JA, et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia 1999; 13: 1901-28.
14. Paulus U, Dreger P, Viehmann K, von Neuhoff N, Schmitz N. Purging peripheral blood progenitor cell grafts from lymphoma cells: quantitative comparison of immunomagnetic CD34 + selection systems. Stem Cells 1997; 15: 297-304.
15. Fouillard L, Laporte JP, Labopin M, et al. Autologous stem-cell transplantation for non-Hodgkin's lymphomas: the role of graft purging and radiotherapy posttransplantation - results of a retrospective analysis on 120 patients autografted in a single institution. J Clin Oncol 1998; 16: 2803-16.
16. Bensinger WI. Should we purge? Bone Marrow Transplant 1998; 21: 113-5.
17. Piro LD, White CA, Grillo-Lopez AJ, et al. Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1999; 10: 655-61.
18. Ghielmini M, Schmitz SF, Burki K, et al. The effect of rituximab on patients with follicular and mantle-cell lymphoma. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 2000; 11(suppl 1): 123-6.
19. Foran JM, Cunningham D, Coiffier B, et al. Treatment of mantle-cell lymphoma with rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response. Ann Oncol 2000; 11(suppl 1): 117-21.
20. Czuczman MS, Grillo-Lopez AJ, McLaughlin P, et al. Clearing of cells bearing the bcl-2 [t(14;18)]. translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy. Ann Oncol 2001; 12: 109-14.
21. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825-33.
22. Buckstein R, Imrie K, Spaner D, et al. Stem cell function and engraftment is not affected by 'in vivo purging' with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma. Semin Oncol 1999; 5(suppl 14): 115-22.
23. Berinstein NL, Buckstein R, Imrie K, et al. Bcl-2 clearance: optimizing outcomes in follicular non-Hodgkin's lymphoma. Bone Marrow 2002; 29(suppl 1): S14-17.
24. Magni M, Di Nicola M, Devizzi L, et al. Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion. Blood 2000; 96: 864-9.
25. Gianni AM, Cortelazzo S, Magni M, Martelli M. Rituximab: enhancing stem cell transplantation in mantle cell lymphoma. Bone Marrow Transplant 2002; 29(suppl 1): S10-13.
26. Marmont AM, Horowitz MM, Gale RP, et al. T-cell depletion of HLA-identical transplants in leukemia. Blood 1991; 78: 2120-30.
27. Chakrabarti S, Kottaridis P, Ogormon P, et al. High incidence of early and late CMV infection and delayed immune reconstitution after allogeneic transplants with nonmyeloablative conditioning using Campath (anti-CD52 antibody). Blood 2000; 96(suppl 1): 586a.
28. Ratanatharathorn V, Bociek RG, Pavletic SZ, et al. Prior therapy with anti-CD20 chimeric antibody (rituximab) may decrease the risk of acute graft-versus-host disease (GVHD) in patients with non-Hodgkin's lymphoma receiving allogeneic stem cell transplantation. Blood 2000; 96(suppl 1): 391a.